![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPAG17 |
Gene summary for SPAG17 |
![]() |
Gene information | Species | Human | Gene symbol | SPAG17 | Gene ID | 200162 |
Gene name | sperm associated antigen 17 | |
Gene Alias | CT143 | |
Cytomap | 1p12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q6Q759 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200162 | SPAG17 | PTC06 | Human | Thyroid | PTC | 4.17e-03 | 1.36e-01 | 0.2057 |
200162 | SPAG17 | ATC13 | Human | Thyroid | ATC | 1.50e-35 | 6.29e-01 | 0.34 |
200162 | SPAG17 | ATC5 | Human | Thyroid | ATC | 1.46e-39 | 6.82e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG17 | SNV | Missense_Mutation | c.5935G>C | p.Glu1979Gln | p.E1979Q | Q6Q759 | protein_coding | tolerated(0.41) | benign(0.005) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPAG17 | SNV | Missense_Mutation | c.6350N>T | p.Pro2117Leu | p.P2117L | Q6Q759 | protein_coding | deleterious(0.03) | possibly_damaging(0.892) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SPAG17 | SNV | Missense_Mutation | novel | c.2634N>G | p.Ile878Met | p.I878M | Q6Q759 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.5295N>A | p.Met1765Ile | p.M1765I | Q6Q759 | protein_coding | tolerated(1) | benign(0) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
SPAG17 | SNV | Missense_Mutation | novel | c.5840N>T | p.Thr1947Ile | p.T1947I | Q6Q759 | protein_coding | tolerated(0.18) | benign(0.02) | TCGA-ZJ-AAXI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | rs761981749 | c.5078N>A | p.Arg1693His | p.R1693H | Q6Q759 | protein_coding | tolerated(0.05) | probably_damaging(0.992) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | c.5858N>T | p.Ser1953Phe | p.S1953F | Q6Q759 | protein_coding | tolerated(0.72) | benign(0.003) | TCGA-A6-2677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
SPAG17 | SNV | Missense_Mutation | rs560266851 | c.323N>T | p.Thr108Met | p.T108M | Q6Q759 | protein_coding | tolerated(0.22) | benign(0) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | c.1475G>A | p.Cys492Tyr | p.C492Y | Q6Q759 | protein_coding | tolerated(0.05) | probably_damaging(0.958) | TCGA-A6-5662-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD | |
SPAG17 | SNV | Missense_Mutation | rs756839531 | c.3821C>T | p.Thr1274Met | p.T1274M | Q6Q759 | protein_coding | deleterious(0.02) | possibly_damaging(0.833) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |